论文部分内容阅读
目的研究分析无创正压通气治疗慢性阻塞性肺疾病合并呼吸衰竭的临床效果。方法选择2013年6月—2014年8月来本院治疗慢性阻塞性肺疾病合并呼吸衰竭的患者82例,随机分成对照组和治疗组,每组各41例。对照组患者采用常规治疗,治疗组患者在对照组治疗基础上给予无创正压通气进行治疗。观察两组患者治疗前后的动脉血气指标(Pa O2、Pa CO2、p H值)及不良反应情况。计量资料采用t检验,计数资料采用χ2检验,P<0.05为差异有统计学意义。结果治疗前,两组患者的动脉血气指标差异均无统计学意义(均P>0.05);治疗后,治疗组患者的Pa O2、p H值明显高于对照组患者[(67.45±3.92)、(59.16±4.27)mm Hg(1 mm Hg=0.133 k Pa)、(7.46±0.03)、(7.38±0.04)],Pa CO2明显低于对照组患者[(58.10±4.88)、(65.37±5.69)mm Hg],差异均有统计学意义(均P<0.05);两组患者的不良反应情况差异均无统计学意义(均P>0.05)。结论无创正压通气治疗慢性阻塞性肺疾病合并呼吸衰竭能有效改善患者动脉血气指标,临床应用不良少,安全有效,具有较高的临床应用价值。
Objective To study the clinical effect of noninvasive positive pressure ventilation on chronic obstructive pulmonary disease (COPD) complicated with respiratory failure. Methods Eighty-two patients with chronic obstructive pulmonary disease and respiratory failure who were admitted to our hospital from June 2013 to August 2014 were randomly divided into control group and treatment group, 41 cases in each group. Patients in the control group were treated with conventional therapy. Patients in the treatment group were treated with noninvasive positive pressure ventilation on the basis of the control group. Arterial blood gas indexes (Pa O2, Pa CO2, p H values) and adverse reactions before and after treatment were observed in both groups. Measurement data using t test, count data using χ2 test, P <0.05 for the difference was statistically significant. Results Before treatment, there was no significant difference in arterial blood gas index between the two groups (all P> 0.05). After treatment, the Pa O2 and p H values in the treatment group were significantly higher than those in the control group [(67.45 ± 3.92), (59.16 ± 4.27) mmHg, (7.46 ± 0.03) and (7.38 ± 0.04), respectively. PaCO 2 was significantly lower than that of the control group [(58.10 ± 4.88) and (65.37 ± 5.69) mm Hg] (all P <0.05). There was no significant difference in adverse reactions between the two groups (all P> 0.05). Conclusion Noninvasive positive pressure ventilation for chronic obstructive pulmonary disease combined with respiratory failure can effectively improve the arterial blood gas in patients with less adverse clinical application, safe and effective, and has high clinical value.